Commentary on “Health economics and the value of therapy in Alzheimer’s disease.” Drug treatment of Alzheimer’s disease: The United Kingdom experience—National Institute for Health and Clinical Excellence guidance and guidelines for dementia

References 

1. A first class service consultation document on quality in the new NHS HSC 1998/113; Health Service Circular, Department of Health, 1 July 1998.
2. Parkinson’s disease. diagnosis and management in primary and secondary care. NICE clinical guideline 35, June 2006. Available at: http://www.guidance.nice.org.uk/CG35.
3. Dementia. supporting people with dementia and their carers in health and social care. NICE clinical guideline 42, November 2006. Available at: http://www.guidance.nice.org.uk/CG42.
4. Donepezil, galantamine, rivastigmine (review) and Memantine for the treatment of Alzheimer’s disease (NICE technology appraisal guidance 111, November 2006). London: National Institute for Health and Clinical Excellence; 2006;Available at: http://www.nice.org.uk/TA111guideline
5. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer’s disease. NICE technology appraisal guidance 19, January 2001. Available at: http://www.cambsmh.nhs.uk.
6. Department of Health. Donepezil, rivastigmine, galantamine and Memantine for the treatment of Alzheimer’s disease. Department of Health response to NICE appraisal consultation 22 March 2005. Available at: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicatoinsPolicyAndGuidance/DH_4106913.
7. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD) 2000: randomised double-blind trial. Lancet. 2004;363:2105–2115
   • Abstract
   • Full Text
   • Full-Text PDF (155 KB)
   • CrossRef
8. Bullock R, Passmore P, Wilkinson D, Howard R, Jones R. Participation in trials should be based on clinical uncertainty, not enforcement. Br Med J [Clin Res]. 2000;320:511
9. Schneider L. AD2000: donepezil in Alzheimer’s disease. [Commentary] Lancet. 2004;363:2100–2101
   • Full Text
   • Full-Text PDF (56 KB)
   • CrossRef
10. Rawlins M, Culyer A. National Institute for Clinical Excellence and its value judgments. Br Med J [Clin Res]. 2004;329:224–227
11. Bosanquet N. QALYs: use in care of the elderly. Geriatr Med. 2005;6:81–87
12. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, et al. Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37:27–32
    • MEDLINE
    • CrossRef
13. Green C. Pharmacoeconomic studies. In:  Ritchie CW,  Ames D,  Masters CL,  Cummings J editor. Therapeutic strategies in dementia. Oxford: Clinical Publishing; 2007;p. 73–88
14. Barnett D. Response from NICE. Geriatr Med. 2005;6:87
15. General Medical Council. Good medical practice. (third edition). London: GMC; 2001;